TITLE

ZELOS/NEKTAR START PHASE 1 TRIAL OF INHALED OSTABOLIN-C

PUB. DATE
November 2006
SOURCE
Worldwide Biotech;Nov2006, Vol. 18 Issue 11, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on a phase 1 clinical trial of an inhaled formulation of parathyroid hormone Ostabolin-C. Zelos Therapeutics Inc. collaborated with Nektar Therapeutics for the development of an inhaleable powder form of the drug in January 2005. Ostabolin-C is a bone formation agent used for the treatment of osteoporosis. The inhaled formulation uses the pocket-sized inhaler from Nektar to deliver a peptide and is designed to provide a portable solution for patients.
ACCESSION #
22828227

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;6/25/2010, Vol. 21 Issue 122, p3 

    This section offers news briefs on clinical trials in the U.S. biopharmaceutical sector as of June 25, 2010. Data reported by Access Pharmaceuticals Inc. showed increased reduction in pain and oral discomfort in patients taking MuGard drug. GlycoMimetics Inc. has initiated a Phase II trial of...

  • Nektar initiates Phase II colorectal cancer trial.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p13 

    The article provides information about Nektar Therapeutics' initiated Phase II clinical trial for its NKTR-102 compound, as a potential treatment for colorectal cancer. The clinical development program is designed to evaluate the safety and efficacy of NKTR-102 for the treatment of patients with...

  • Nektar Restructuring to Build Up Pipeline.  // Bioworld Week;2/18/2008, Vol. 16 Issue 7, p3 

    The article reports on the corporate reorganization carried out by Nektar Therapeutics Inc. in the U.S. It states that the move aims towards a shift on the company's drug delivery services towards the development and manufacture of drugs. Nektar aims to focus on the development of pulmonary...

  • Nektar Therapeutics: Collaborating in Compliance. Summerfield, Brian // Chief Learning Officer;Oct2004, Vol. 3 Issue 10, p46 

    This article reports that Nektar Therapeutics, based in San Carlos, California, provides drug-delivery technologies to enable the development of a wide variety of high-value therapeutics. The company's drug-delivery capabilities are designed to help its biotechnology and pharmaceutical partners...

  • NEKTAR GETS $17.6 MILLION FROM AFFYMAX PACT FOR HEMATIDE.  // Worldwide Biotech;Sep2006, Vol. 18 Issue 9, p3 

    The article reports on a payment received by Nektar Therapeutics under an undisclosed license agreement with Affymax Inc. for hematide. The deal has been triggered by Affymax's entry into a global agreement with Takeda Inc. to develop and commercialize its hematide lead product. Hematide is...

  • CLINIC ROUNDUP.  // BioWorld Today;1/14/2009, Vol. 20 Issue 8, p8 

    This section offers news briefs on clinical trials. AcelRx Pharmaceuticals Inc. reported positive results from a Phase I study evaluating the safety, tolerability and efficacy of the company's proprietary sublingual sufentanil and triazolam NanoTab combination product candidate (ARX-03). Aiko...

  • Nektar Halts Partnership Talks Over Exubera Cancer Concerns. Young, Donna // BioWorld Today;4/10/2008, Vol. 19 Issue 70, p1 

    The article reports on the decision of Nektar Therapeutics Inc. to stop partnership negotiations involving MannKind's Exubera after a new analysis of clinical trial data showed an increased risk of lung cancer. As a result, shares of Nektar declined by 25% or $1.80, to close at $5.39. Mannkind's...

  • Nektar Therapeutics initiates Phase I acute pain study.  // PharmaWatch: CNS;May2012, Vol. 11 Issue 5, p13 

    The article reports on the initation of Nektar Therapeutics' Phase I clinical study on the pharmacokinetics and safety of NKTR-192, a mu-opioid analgesic candidate. It notes that the study discovers a decline in self-administration of NKTR-192 when it comes to forecasting the abuse liability of...

  • ECCO Meeting.  // BioWorld Today;9/28/2007, Vol. 18 Issue 189, p4 

    The article announces the findings of Nektar Therapeutics Inc. regarding preclinical results on NKTR-102 (PEG-irinotecan) in September 2007. Researchers say that an irinotecan-resistant mouse xenograft model showed remarkable dose-related suppression of tumor growth. The drug is in its Phase I...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics